Booth Jessica L, Ross Vernon H, Nelson Kenneth E, Harris Lynnette, Eisenach James C, Pan Peter H
From the Department of Anesthesiology, Section on Obstetric Anesthesiology, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Anesthesiology. 2017 Jul;127(1):50-57. doi: 10.1097/ALN.0000000000001669.
The addition of opioids to epidural local anesthetic reduces local anesthetic consumption by 20% but at the expense of side effects and time spent for regulatory compliance paperwork. Epidural neostigmine also reduces local anesthetic use. The authors hypothesized that epidural bupivacaine with neostigmine would decrease total hourly bupivacaine use compared with epidural bupivacaine with fentanyl for patient-controlled epidural analgesia.
A total of 215 American Society of Anesthesiologists physical status II, laboring parturients requesting labor epidural analgesia consented to the study and were randomized to receive 0.125% bupivacaine with the addition of either fentanyl (2 μg/ml) or neostigmine (2, 4, or 8 μg/ml). The primary outcome was total hourly local anesthetic consumption, defined as total patient-controlled epidural analgesia use and top-ups (expressed as milliliters of 0.125% bupivacaine) divided by the infusion duration. A priori analysis determined a group size of 35 was needed to have 80% power at α = 0.05 to detect a 20% difference in the primary outcome.
Of 215 subjects consented, 151 patients were evaluable. Demographics, maternal and fetal outcomes, and labor characteristics were similar among groups. Total hourly local anesthetic consumption did not differ among groups (P = 0.55). The total median hourly bupivacaine consumption in the fentanyl group was 16.0 ml/h compared with 15.3, 14.6, and 16.2 ml/h in the 2, 4, and 8 μg/ml neostigmine groups, respectively (P = 0.55).
The data do not support any difference in bupivacaine requirements for labor patient-controlled epidural analgesia whether patients receive epidural bupivacaine with 2 to 8 μg/ml neostigmine or epidural bupivacaine with 2 μg/ml fentanyl.
在硬膜外局麻药物中添加阿片类药物可使局麻药物用量减少20%,但会产生副作用,并增加用于监管合规文书工作的时间。硬膜外新斯的明也可减少局麻药物的使用。作者推测,与用于患者自控硬膜外镇痛的含芬太尼的硬膜外布比卡因相比,含新斯的明的硬膜外布比卡因会减少每小时布比卡因的总用量。
共有215例美国麻醉医师协会身体状况分级为Ⅱ级、要求进行分娩硬膜外镇痛的产妇同意参与本研究,并被随机分为两组,分别接受添加了芬太尼(2μg/ml)或新斯的明(2、4或8μg/ml)的0.125%布比卡因。主要结局指标为每小时局麻药物总用量,定义为患者自控硬膜外镇痛的总用量及追加用量(以0.125%布比卡因的毫升数表示)除以输注持续时间。预先分析确定,每组需要35例患者,才能在α = 0.05时具有80%的检验效能,以检测主要结局指标有20%的差异。
在215例同意参与研究的受试者中,151例患者可进行评估。各组之间的人口统计学特征、母婴结局及分娩特征相似。各组每小时局麻药物总用量无差异(P = 0.55)。芬太尼组布比卡因每小时总用量中位数为16.0 ml/h,而新斯的明2、4和8μg/ml组分别为15.3、14.6和16.2 ml/h(P = 0.55)。
对于分娩患者自控硬膜外镇痛,无论患者接受含2至8μg/ml新斯的明的硬膜外布比卡因还是含2μg/ml芬太尼的硬膜外布比卡因,数据均不支持布比卡因需求量存在差异。